Overview
Mark Sulkowski, MD, is a Professor of Medicine at the Johns Hopkins University School of Medicine and the Director of the Division of Infectious Diseases at Johns Hopkins Bayview Medical Center. He also serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine and is the Senior Associate Dean for Clinical Trials. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine. Prof. Sulkowski has been the principal investigator for more than 120 clinical trials related to the management of viral hepatitis B and C in persons with and without HIV co-infection. He was the global principal investigator for more than a dozen trials, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the past-chair of the Hepatitis Transformative Sciences Group of the National Institute of Health-funded adult AIDS Clinical Trials Group (ACTG) where he led translational studies of liver disease, namely hepatitis B and C virus. He is an elected member of the American Society for Clinical Investigation (2011) and the American Association of Physicians (2017). Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). With more than 300 peer-reviewed articles, he is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Clinical Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017, 2018 and 2019, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries.
Dr. Sulkowski is rated as an Experienced provider by MediFind in the treatment of COVID-19. His top areas of expertise are Hepatitis C, Hepatitis, HIV/AIDS, and Hepatitis B.
His clinical research consists of co-authoring 287 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles and participated in 1 clinical trial in the study of COVID-19.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
Falls Concourse STE 412, Lutherville, MD 21093
1717 East Monument Street, Park Building, Ground Level, Baltimore, MD 21287
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
10 Clinical Trials
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Dr. Robin Avery is an infectious disease physician who joined the Johns Hopkins faculty in 2012, with two decades of experience in transplant infectious disease. She is a past chair of the American Society of Transplantation (AST) Infectious Disease Community of Practice, was a co-editor of the first edition of the AST ID Guidelines, and serves on a Guidelines Committee for the Infectious Disease Society of America (IDSA) on immunizations in the immunocompromised host. She was the founding head of the Transplant Infectious Disease Section at the Cleveland Clinic and served as the founding director of the Cleveland Clinic Transplant ID Special Fellowship, authoring a curriculum that served as the basis for curricula later endorsed by the AST and IDSA. Her clinical and research interests include pre-transplant donor and recipient evaluation, and prevention and treatment of post-transplant infections, particularly transplant-associated viruses, viral load monitoring, novel therapies for CMV, hypogammaglobulinemia, immunizations, and strategies for safer living post-transplant. She has a strong interest in patient education and co-authored the script for a video designed to educate patients on decreasing post-transplant infection risks. Dr. Avery is rated as a Distinguished provider by MediFind in the treatment of COVID-19. Her top areas of expertise are Cytomegalic Inclusion Disease, Cytomegalovirus Infection, COVID-19, and Sepsis.
Johns Hopkins Bayview Medical Center
Dr. Werbel is a physician-scientist who provides consultative care for patients at Johns Hopkins who experience infectious disease complications before and after organ transplant, as well as in the setting of solid tumors or blood cancers. His research with the Johns Hopkins Transplant Research Center uses a combination of epidemiological and laboratory methods to better personalize the prevention of infectious complications among patients with complex immunodeficiencies. This includes using national cohort studies and clinical trials to optimize the use of vaccines and other prophylactic therapies for high-risk immunosuppressed populations. Dr. Werbel is rated as an Advanced provider by MediFind in the treatment of COVID-19. His top areas of expertise are COVID-19, Severe Acute Respiratory Syndrome (SARS), HIV/AIDS, and Hepatitis.
Kathleen Neuzil is an Infectious Disease provider in Baltimore, Maryland. Dr. Neuzil is rated as a Distinguished provider by MediFind in the treatment of COVID-19. Her top areas of expertise are Typhoid Fever, Salmonella Enterocolitis, Flu, and COVID-19.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Elite
- HepatitisDr. Sulkowski isElite. Learn about Hepatitis.
- Hepatitis CDr. Sulkowski isElite. Learn about Hepatitis C.
- HIV/AIDSDr. Sulkowski isElite. Learn about HIV/AIDS.
- Distinguished
- Hepatitis BDr. Sulkowski isDistinguished. Learn about Hepatitis B.
- Experienced
- AIDS Dementia ComplexDr. Sulkowski isExperienced. Learn about AIDS Dementia Complex.
- AIDS Dysmorphic SyndromeDr. Sulkowski isExperienced. Learn about AIDS Dysmorphic Syndrome.
- COVID-19Dr. Sulkowski isExperienced. Learn about COVID-19.
- End-Stage Renal Disease (ESRD)Dr. Sulkowski isExperienced. Learn about End-Stage Renal Disease (ESRD).
- Liver FailureDr. Sulkowski isExperienced. Learn about Liver Failure.
- MyelitisDr. Sulkowski isExperienced. Learn about Myelitis.